Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 421

1.

Evaluation of Light Fluence Distribution Using an IR Navigation System for HPPH-mediated Pleural Photodynamic Therapy (pPDT).

Zhu TC, Ong Y, Kim MM, Liang X, Finlay JC, Dimofte A, Simone Nd CB, Friedberg JS, Busch TM, Glatstein E, Cengel KA.

Photochem Photobiol. 2019 Sep 25. doi: 10.1111/php.13166. [Epub ahead of print]

PMID:
31556122
2.

Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.

Rengan R, Mick R, Pryma DA, Lin LL, Christodouleas J, Plastaras JP, Simone CB 2nd, Gupta AK, Evans TL, Stevenson JP, Langer CJ, Kucharczuk J, Friedberg J, Lam S, Patsch D, Hahn SM, Maity A.

JAMA Oncol. 2019 Aug 22. doi: 10.1001/jamaoncol.2019.2095. [Epub ahead of print]

PMID:
31436839
3.

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma.

Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, Smith SM, Friedberg JW.

Blood. 2019 Jul 22. pii: blood.2019000719. doi: 10.1182/blood.2019000719. [Epub ahead of print]

PMID:
31331918
4.

Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.

Loh KP, Baran A, Lee CY, Alshaibani A, Rutherford SC, Hu J, Casulo C, Barr PM, Friedberg JW, Reagan PM.

Leuk Lymphoma. 2019 Jul 8:1-4. doi: 10.1080/10428194.2019.1639172. [Epub ahead of print] No abstract available.

PMID:
31282781
5.

A Tailored Behavioral Intervention to Promote Adherence to the DASH Diet.

Rodriguez MA, Friedberg JP, DiGiovanni A, Wang B, Wylie-Rosett J, Hyoung S, Natarajan S.

Am J Health Behav. 2019 Jul 1;43(4):659-670. doi: 10.5993/AJHB.43.4.1.

PMID:
31239010
6.

Management of Clinically Lymph Node-Positive Malignant Pleural Mesothelioma.

Verma V, Wegner RE, Adeberg S, Horne ZD, Grover S, Friedberg JS, Simone CB 2nd.

Semin Thorac Cardiovasc Surg. 2019 Jun 19. pii: S1043-0679(19)30177-7. doi: 10.1053/j.semtcvs.2019.06.004. [Epub ahead of print]

PMID:
31226401
7.

Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.

Amin W, Linkov F, Landsittel DP, Silverstein JC, Bashara W, Gaudioso C, Feldman MD, Pass HI, Melamed J, Friedberg JS, Becich MJ.

Version 3. F1000Res. 2018 Aug 3 [revised 2019 Jan 1];7:1184. doi: 10.12688/f1000research.15512.3. eCollection 2018.

8.

Integrating Assessment of Sarcopenia into Decision-making for Allogeneic Hematopoietic Cell Transplantation: Ready for Prime Time?

Loh KP, Dunne RF, Friedberg JW, Mohile SG.

J Natl Cancer Inst. 2019 Feb 14. pii: djy233. doi: 10.1093/jnci/djy233. [Epub ahead of print] No abstract available.

PMID:
31220297
9.

Contact sport participation and chronic traumatic encephalopathy are associated with altered severity and distribution of cerebral amyloid angiopathy.

Standring OJ, Friedberg J, Tripodis Y, Chua AS, Cherry JD, Alvarez VE, Huber BR, Xia W, Mez J, Alosco ML, Nicks R, Mahar I, Pothast MJ, Gardner HM, Meng G, Palmisano JN, Martin BM, Dwyer B, Kowall NW, Cantu RC, Goldstein LE, Katz DI, Stern RA, McKee AC, Stein TD.

Acta Neuropathol. 2019 Sep;138(3):401-413. doi: 10.1007/s00401-019-02031-x. Epub 2019 Jun 10.

PMID:
31183671
10.

Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs.

Zackon AYL, Ayers AA, Yeager KA, Somma ML, Friedberg JW, Flowers CR, Nastoupil LJ.

Leuk Lymphoma. 2019 Oct;60(10):2356-2364. doi: 10.1080/10428194.2019.1594217. Epub 2019 Jun 4.

PMID:
31164024
11.

Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells.

Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S.

Mol Cancer Ther. 2019 Jun;18(6):1181. doi: 10.1158/1535-7163.MCT-19-0471. No abstract available.

12.

Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo.

Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S.

Mol Cancer Ther. 2019 Jun;18(6):1180. doi: 10.1158/1535-7163.MCT-19-0470. No abstract available.

13.

Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo.

Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S.

Mol Cancer Ther. 2019 Jun;18(6):1179. doi: 10.1158/1535-7163.MCT-19-0469. No abstract available.

14.

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.

Friedberg JS, Culligan MJ, Tsao AS, Rusch V, Sepesi B, Pass HI, Bueno R, Burt B, Sugarbaker DJ, de Perrot M, Adjei AA, Adusumilli PS, Hirsch FR, Malik SM, Harpole DJ Jr.

J Thorac Oncol. 2019 Aug;14(8):1343-1353. doi: 10.1016/j.jtho.2019.04.029. Epub 2019 May 25. Review.

PMID:
31136816
15.

Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma.

Berger I, Cengel KA, Simone CB 2nd, Alley EW, Roshkovan L, Haas AR, Patel AM, Khalid U, Culligan MJ, McNulty S, Singhal S, Friedberg JS, Katz SI.

Lung Cancer. 2019 Jun;132:94-98. doi: 10.1016/j.lungcan.2019.03.026. Epub 2019 Mar 26.

PMID:
31097101
16.

Management of Malignant Pleural Mesothelioma in the Elderly Population.

Verma V, Wegner RE, Ludmir EB, Hasan S, Colonias A, Grover S, Friedberg JS, Simone CB 2nd.

Ann Surg Oncol. 2019 Aug;26(8):2357-2366. doi: 10.1245/s10434-019-07351-6. Epub 2019 Apr 22.

PMID:
31011908
17.

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP.

J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2.

PMID:
30939090
18.

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.

Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM, Sureda A, Moskowitz A, Friedberg JW, Inwards DJ, Herrera AF, Kharfan-Dabaja MA, Reddy N, Montoto S, Robinson SP, Abutalib SA, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales MA, Carpenter P, Savani BN, Hamadani M.

JAMA Oncol. 2019 May 1;5(5):715-722. doi: 10.1001/jamaoncol.2018.6278.

PMID:
30816957
19.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW.

Blood. 2019 Apr 18;133(16):1762-1765. doi: 10.1182/blood-2018-08-870915. Epub 2019 Feb 5.

PMID:
30723079
20.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.

Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ.

Leuk Lymphoma. 2019 Aug;60(8):1934-1941. doi: 10.1080/10428194.2018.1563691. Epub 2019 Jan 10.

PMID:
30628511
21.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.

Clin Cancer Res. 2019 Mar 15;25(6):1718-1726. doi: 10.1158/1078-0432.CCR-18-2435. Epub 2019 Jan 7.

PMID:
30617130
22.

Identifying and Chronicling Childhood Lead Poisoning Prevention Program Achievements With "Success Stories".

Lockamy-Kassim E, Friedberg J, Newby C, Lecours C, Credle K, Leonard M.

J Public Health Manag Pract. 2019 Jan/Feb;25 Suppl 1, Lead Poisoning Prevention:S111-S114. doi: 10.1097/PHH.0000000000000874.

23.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.

Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

PMID:
30501868
24.

Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.

Verma V, Ahern CA, Berlind CG, Lindsay WD, Grover S, Friedberg JS, Simone CB 2nd.

J Thorac Cardiovasc Surg. 2019 Feb;157(2):758-766.e1. doi: 10.1016/j.jtcvs.2018.10.039. Epub 2018 Oct 22.

PMID:
30454981
25.

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.

Qu X, Li H, Braziel RM, Passerini V, Rimsza LM, Hsi ED, Leonard JP, Smith SM, Kridel R, Press O, Weigert O, LeBlanc M, Friedberg JW, Fang M.

Blood. 2019 Jan 3;133(1):81-93. doi: 10.1182/blood-2018-07-865428. Epub 2018 Nov 16.

PMID:
30446494
26.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.

Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, Moore J, Baloga E, Zent CS, Barr PM.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):41-47. doi: 10.1016/j.clml.2018.10.005. Epub 2018 Oct 13.

PMID:
30409718
27.

Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation.

Adhikary G, Grun D, Alexander HR, Friedberg JS, Xu W, Keillor JW, Kandasamy S, Eckert RL.

Oncotarget. 2018 Oct 2;9(77):34495-34505. doi: 10.18632/oncotarget.26130. eCollection 2018 Oct 2.

28.

Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.

Schonewolf CA, Heskel M, Doucette A, Singhal S, Frick MA, Xanthopoulos EP, Corradetti MN, Friedberg JS, Pechet TT, Christodouleas JP, Levin W, Berman A, Cengel KA, Verma V, Hahn SM, Kucharczuk JC, Rengan R, Simone CB 2nd.

Clin Lung Cancer. 2019 Jan;20(1):e63-e71. doi: 10.1016/j.cllc.2018.09.004. Epub 2018 Sep 20.

PMID:
30337269
29.

Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis.

Rice SR, Molitoris JK, Vyfhuis MAL, Edelman MJ, Burrows WM, Feliciano J, Nichols EM, Suntharalingam M, Donahue J, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P.

Clin Lung Cancer. 2019 Jan;20(1):e107-e114. doi: 10.1016/j.cllc.2018.09.014. Epub 2018 Sep 24.

PMID:
30337268
30.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
31.

Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.

David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):781-787. doi: 10.1016/j.clml.2018.08.014. Epub 2018 Aug 29.

PMID:
30262330
32.

Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.

Verma V, Ahern CA, Berlind CG, Lindsay WD, Shabason J, Sharma S, Culligan MJ, Grover S, Friedberg JS, Simone CB 2nd.

Clin Lung Cancer. 2018 Nov;19(6):e901-e912. doi: 10.1016/j.cllc.2018.08.007. Epub 2018 Aug 29.

PMID:
30224273
33.

Burkitt lymphoma- a rare but challenging lymphoma.

Casulo C, Friedberg JW.

Best Pract Res Clin Haematol. 2018 Sep;31(3):279-284. doi: 10.1016/j.beha.2018.07.013. Epub 2018 Jul 23. Review.

PMID:
30213397
34.

Povidone-iodine results in rapid killing of thymic epithelial tumour cells through cellular fixation†.

Lee HS, Jang HJ, Lo EM, Truong CY, Groth SS, Friedberg JS, Sugarbaker DJ, Burt BM.

Interact Cardiovasc Thorac Surg. 2019 Mar 1;28(3):353-359. doi: 10.1093/icvts/ivy248.

35.

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen R, Candia AF, Coffman RL, Levy R.

Cancer Discov. 2018 Oct;8(10):1258-1269. doi: 10.1158/2159-8290.CD-18-0743. Epub 2018 Aug 28.

36.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D.

Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6.

PMID:
30082475
37.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL.

Blood. 2018 Sep 6;132(10):1013-1021. doi: 10.1182/blood-2018-01-827246. Epub 2018 Jul 26.

38.

Progress in Advanced-Stage Follicular Lymphoma.

Friedberg JW.

J Clin Oncol. 2018 Aug 10;36(23):2363-2365. doi: 10.1200/JCO.2018.79.3083. Epub 2018 Jun 1. No abstract available.

PMID:
29856695
39.

A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.

Davis RW 4th, Papasavvas E, Klampatsa A, Putt M, Montaner LJ, Culligan MJ, McNulty S, Friedberg JS, Simone CB 2nd, Singhal S, Albelda SM, Cengel KA, Busch TM.

Lasers Surg Med. 2018 Jul;50(5):440-450. doi: 10.1002/lsm.22934. Epub 2018 May 25.

40.

Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis.

Verma V, Ahern CA, Berlind CG, Lindsay WD, Grover S, Culligan MJ, Friedberg JS, Simone CB 2nd.

Lung Cancer. 2018 Jun;120:7-13. doi: 10.1016/j.lungcan.2018.03.019. Epub 2018 Mar 21.

PMID:
29748018
41.

Intrapleural Therapy for Empyema in the Setting of a Bronchopleural Fistula: A Novel Use of an Intrabronchial Valve.

Leiter N, Pickering EM, Sangwan YS, Burrows WM, Friedberg JS, Sachdeva A.

Ann Thorac Surg. 2018 Sep;106(3):e111-e113. doi: 10.1016/j.athoracsur.2018.03.023. Epub 2018 Apr 13.

PMID:
29660355
42.

Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.

Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW.

Br J Haematol. 2019 Feb;184(4):660-663. doi: 10.1111/bjh.15149. Epub 2018 Apr 2. No abstract available.

PMID:
29611177
43.

Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.

Vyfhuis MAL, Burrows WM, Bhooshan N, Suntharalingam M, Donahue JM, Feliciano J, Badiyan S, Nichols EM, Edelman MJ, Carr SR, Friedberg J, Henry G, Stewart S, Sachdeva A, Pickering EM, Simone CB 2nd, Feigenberg SJ, Mohindra P.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):445-452. doi: 10.1016/j.ijrobp.2018.02.003. Epub 2018 Feb 13.

PMID:
29559292
44.

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.

Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, LeBlanc M, Bartlett N, Leonard JP, Smith SM, Press OW, Friedberg JW.

Haematologica. 2018 Apr;103(4):e151-e153. doi: 10.3324/haematol.2017.175059. Epub 2018 Feb 22. No abstract available.

45.

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.

Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW.

Lancet Haematol. 2018 Mar;5(3):e102-e108. doi: 10.1016/S2352-3026(18)30001-2. Epub 2018 Jan 26.

46.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW.

J Clin Oncol. 2018 Mar 1;36(7):697-703. doi: 10.1200/JCO.2017.74.5083. Epub 2018 Jan 22.

47.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM.

Blood Adv. 2017 Dec 11;1(26):2600-2609. doi: 10.1182/bloodadvances.2017009472. eCollection 2017 Dec 12.

48.

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, Laport GG, Popplewell LL, Holmberg LA, Smith SM, LeBlanc M, Forman SJ, Fisher RI, Stiff PJ.

Biol Blood Marrow Transplant. 2018 Apr;24(4):700-707. doi: 10.1016/j.bbmt.2017.12.798. Epub 2017 Dec 28.

49.

Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].

Vyfhuis MAL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano J, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P.

Lung Cancer. 2018 Feb;116:105. doi: 10.1016/j.lungcan.2017.12.011. Epub 2017 Dec 27. No abstract available.

PMID:
29289353
50.

A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.

Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, Von Gehr A, LeBlanc M, Fisher RI, Smith SM, Friedberg JW.

Am J Hematol. 2018 Aug;93(4):486-493. doi: 10.1002/ajh.25010. Epub 2018 Jan 25.

Supplemental Content

Loading ...
Support Center